Dermata Therapeutics Inc.
DRMA evidence brief
What we can confirm
- BioSniper Score:
- 6.8 / 10
- Market Cap:
- $5.9M
What it means
What to watch
Prepared research question
What matters most for DRMA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DRMA
Dermata Therapeutics Inc. (DRMA) is a biopharmaceutical company developing topical treatments for acne and other skin conditions, with its first commercial product launch expected in August 2026.
Key risk: Cash runway limited
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$5.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Dermata Therapeutics Inc..
Dermata Therapeutics Inc. (DRMA) is a biopharmaceutical company developing topical treatments for acne and other skin conditions, with its first commercial product launch expected in August 2026.
- Cash & equivalents of $4.4M as of 2026-06-30 [sec].
- Net income of -$3.0M as of 2026-06-30 [sec].
- Shareholders' equity of $3.5M as of 2026-06-30 [sec].
- First commercial product, Tome™ Foundational Treatment, expected to launch on August 25, 2026 [news · published 2026-08-11].
- Accumulated deficit of $71.4 million as of September 30, 2025 [sec_mda · as of 2025-11-14].
What works
- First commercial product launch (Tome™ Foundational Treatment) scheduled for August 25, 2026, indicating progress toward revenue generation [news · published 2026-08-11].
- Phase 3 study for DMT310 in acne vulgaris has been initiated, showing advancement in clinical development [catalyst].
What to weigh
- Cash runway is estimated only into the fourth quarter of 2026, suggesting a need for additional capital in the near term [sec_mda · as of 2026-08-11].
- The company has an accumulated deficit of $71.4 million as of September 30, 2025, and expects to continue incurring net losses [sec_mda · as of 2025-11-14].
- Future funding requirements are heavily dependent on product revenues from the first launch, which cannot be estimated at this time [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Cash runway into Q4 2026
“We believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026.”
SEC MD&A · August 11, 2026
First commercial product launch date
“Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026”
News · August 11, 2026
Accumulated deficit
“As of September 30, 2025, we had an accumulated deficit of $71.4 million.”
SEC MD&A · November 14, 2025
Phase 3 study start
“Phase3_Start: A PHASE 3 STUDY OF TOLERABILITY, SAFETY, AND EFFICACY, OF DMT310 IN PATIENTS WITH ACNE VULGARIS”
Catalysts · December 8, 2023
Catalyst timeline
- 2023-12-08 · Phase 3 study start for DMT310 in acne vulgaris — Initiation of a Phase 3 tolerability, safety, and efficacy study for DMT310 in patients with acne vulgaris.
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash and equivalents of $4.4M as of 2026-06-30 are expected to fund operations only into Q4 2026 [sec_mda · as of 2026-08-11].
- Accumulated deficit growing — Accumulated deficit reached $71.4M as of September 30, 2025, with continued net losses expected [sec_mda · as of 2025-11-14].
- Revenue dependence uncertain — Future funding heavily depends on product revenues from first launch, which cannot be estimated [sec_mda · as of 2026-08-11].
What to watch
- First commercial product launch of Tome™ Foundational Treatment on August 25, 2026 [news · published 2026-08-11].
- Progress and results of the Phase 3 study for DMT310 in acne vulgaris [catalyst].
- Ability to raise additional capital given cash runway ending in Q4 2026 [sec_mda · as of 2026-08-11].
- Financial results and cash position updates in subsequent quarterly reports.
Sources: Catalysts · News · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Dermata Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Dermata Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.53 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 6.4%
- Days to cover
- 0.1
- Shares short
- 200,344
- Daily short volume (Oct 9, 2026)
- 21.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DRMA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Dermata Therapeutics Inc.?
Dermata Therapeutics Inc. (DRMA) is a biopharmaceutical company developing topical treatments for acne and other skin conditions, with its first commercial product launch expected in August 2026.
Who is the CEO of Dermata Therapeutics Inc.?
Mr. Gerald T. Proehl is the chief executive officer of Dermata Therapeutics Inc. (DRMA).
Where is Dermata Therapeutics Inc. headquartered?
Dermata Therapeutics Inc. (DRMA) is headquartered in San Diego, CA, United States.
What therapeutic areas does Dermata Therapeutics Inc. focus on?
Dermata Therapeutics Inc. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.